Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Prostate Cancer
Interventions
DRUG

PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC

"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Patients will receive standard of care radiation therapy (SBRT)

Trial Locations (1)

10065'

RECRUITING

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Weill Medical College of Cornell University

OTHER